Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Surgical treatment outcomes on early-stages of non-small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015
Improving survival for NSCLC patients in the national lung cancer audit Source: International Congress 2015 – Quality management in lung cancer Year: 2015
Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014
Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013
Algorithm of preoperative N-staging of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013
Treatment of advanced non-small cell lung cancer with trofosfamide Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013
Checkpointinhibition in lung cancer – How to distinguish pseudoprogression from progressive disease Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
Lung cancer in women: What are particularities? Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014
Lung cancer, has it changed in the last ten years? Source: International Congress 2015 – Quality management in lung cancer Year: 2015
Futile thoracotomy in lung cancer Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013
Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014
Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
The prognostic value of D-dimer in lung carcinoma Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Survival in lung cancer: Associated factors in Tunisian patients Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features Year: 2015
Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014
Does IASLC/ATS/ERS classification of lung adenocarcinoma impacts prognosis? Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013
EBUS-TBNA for nodal restaging and relapse in lung cancer Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014